Users online: 2097    [ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2017, Volume : 10, Issue : 9
First page : ( 3233) Last page : ( 3236)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2017.00573.X

Linagliptin: A Review on Therapeutic Role in Diabetes Mellitus.

Aher Smita S.1, Gajare Saroj P.2,*, Saudagar Ravindra B.1

1Department of Pharmaceutical Chemistry, R. G. Sapkal College of Pharmacy, Anjaneri, Nasik

2Department of Quality Assurance Techniques, R. G. Sapkal College of Pharmacy, Anjaneri, Nasik

*Corresponding Author E-mail: sarojgajare19@gmail.com

Online published on 16 May, 2018.


Diabetes mellitus is a chronic condition prevalent worldwide. It is estimated that more than 246 million individuals have diabetes, with this number expected to increase to 366 million by the year 2030. The chronic hyperglycemia of diabetes is associated with long term damage to various organs, including the eyes, kidneys, nervous system, heart, and vasculature. India has a long history regarding the epidemiology of diabetes. In an effort to optimize glycemic control and also to reduce the burden of diabetic complications, several classes of oral hypoglycemic agents have been developed. Linagliptin has now been on the market and has been established as the first-line agent of choice for the management of type 2 diabetes. In this way, linagliptin is anticipated to reduce insulin resistance, contribute to weight loss, and play a significant role in the improvement of cardiovascular outcomes.



Linagliptin, Diabetes, Hyperglycemia.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
575,644,060 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.